Quality of life after transcatheter tricuspid valve repair: results from the Tri.FR trial

Quality of life after transcatheter tricuspid valve repair: results from the Tri.FR trial

Abstract Aims In the Tri.FR trial, tricuspid transcatheter edge‐to‐edge repair (T‐TEER) reduced severity of tricuspid regurgitation (TR) and improved the composite clinical score, driven by patient‐reported outcomes. The purpose of this study was to describe the longitudinal impact of T‐TEER on diff...

Full description

Saved in:
Bibliographic Details
Main Authors: Sabina Istratoaie, Pascal deGroote, Nicole Karam, Jean‐Noel Trochu, Guillaume Leurent, Augustin Coisne, Pierre‐Yves Le Roux, Anne Ganivet, Anne Bernard, Antoinette Neylon, Romain Pierrard, Florent Le Ven, François Picard, Nicolas Piriou, Thierry Laperche, Jerome Jouan, Amedeo Anselmi, Vincent Auffret, Emmanuel Oger, Erwan Donal
Format: Article
Language:English
Published: Wiley 2025-08-01
Series:ESC Heart Failure
Subjects:
Tricuspid valve regurgitation
Transcatheter valve
Quality of life
Online Access:https://doi.org/10.1002/ehf2.15327
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Aims In the Tri.FR trial, tricuspid transcatheter edge‐to‐edge repair (T‐TEER) reduced severity of tricuspid regurgitation (TR) and improved the composite clinical score, driven by patient‐reported outcomes. The purpose of this study was to describe the longitudinal impact of T‐TEER on different dimensions and items of quality of life compared with guideline‐directed medical treatment (OMT) alone. Methods and results Patients were randomized to T‐TEER +OMT (n = 152) or OMT alone (n = 148). Health status was assessed at baseline, 6 weeks, 6 months, and 1 year using the Kansas City Cardiomyopathy Questionnaire (KCCQ) and the Minnesota Living with Heart Failure (MLHF) Questionnaire. Mixed effects linear regression analysed changes over time. Patients receiving T‐TEER + OMT experienced a significant increase in KCCQ overall summary score (KCCQ‐OS) at all time points: +17.0 points (95% confidence interval [CI] 13.1–21.5) at 6 weeks, +15.9 points (95% CI 11.2–20.6) at 6 months, and +18.7 points (95% CI 13.8–23.6) at 1 year. The mean between‐group difference in KCCQ‐OS was +10.3 points (95% CI 5.6–15.0) in favour of T‐TEER + OMT, evident at 6 weeks and sustained for 1 year. Similarly, MLHF total scores improved significantly in the T‐TEER group (mean between‐group difference −8.61 points, 95% CI –12.6 to −4.6), including physical (−3.9, 95% CI –5.9 to −1.9) and emotional (−2.2, 95% CI –3.4 to −1.0) subscales. Conclusions Compared with OMT alone, T‐TEER resulted in substantial, multidimensional, and sustained improvements in patient‐reported quality of life. These findings reinforce the value of T‐TEER in managing severe symptomatic TR.
ISSN:2055-5822

Similar Items